Sparrow BioAcoustics Names Gary Lickovitch as Chief Commercial Officer
Summary
Gary joins Sparrow at a pivotal moment following the launch of Stethophone® PRO, a groundbreaking innovation that is set to transform accessibility to early detection of structural and rhythmic heart issues while also significantly impacting provider economics. ST. JOHNS, NL, April 24, 2025 /PRNewswire-PRWeb/ -- Sparrow BioAcoustics, the company behind the worlds first Software as a Medical Device (SaMD) cardiac AI that runs entirely on smartphones, today announced the appointment of Gary Lickovitch as Chief Commercial Officer. Gary joins Sparrow at a pivotal moment following the launch of Stethophone PRO, a groundbreaking innovation that is set to transform accessibility to early detection of structural and rhythmic heart issues while also significantly impacting provider economics. "Garys deep expertise in commercial strategy, market expansion, and growth in the medtech space makes him the perfect addition to our leadership team," said Mark Opauszky, CEO of Sparrow BioAcoustics. "His track record of scaling businesses and driving adoption of transformative medical technologies aligns with our vision of making high-quality cardiac screening accessible to millions globally."